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Summary The ‘holy grail’ in radiation oncology is to improve
the outcome of radiation therapy (RT) with a radiosensitizer—a
systemic chemical/biochemical agent that additively or syner-
gistically sensitizes tumor cells to radiation in the absence of
significant toxicity. Similar to the oxygen effect, in which DNA
bases modified by reactive oxygen species prevent repair of the
cellular radiation damage, these compounds in general magnify
free radical formation, leading to the permanent Bfixation^ of
the resultant chemical change in the DNA structure. The
purpose of this review is to present the origin story of the
radiosensitizer, RRx-001, which emerged from the aerospace
industry. The activity of RRx-001 as a chemosensitizer in
multiple tumor types and disease states including malaria,
hemorrhagic shock and sickle cell anemia, are the subject
of future reviews.
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Introduction
The origin story of the Phase II anticancer agent RRx-001 is
presented in this review.
Unlike the pharmaceutical industry’s emphasis on Bme
too^ drugs that slavishly mimic existing chemical compounds
(e.g., statins, antibiotics, H1 and H2 histamine blockers etc.),
RRx-001, having been derived from the aerospace and
defense sector, is the prototype of a pharmacologically
unprecedented and decidedly Bnon-me too^ chemical class
called dinitroazetidines.
The strategic decision to move forward a compound hinges
on a risk benefit analysis. In this case the development of
RRx-001 was predicated on the reasonable anticipation of
non-toxicity, even though the benefits initially were unknown.
Given that the detonation of nitrogenous combustibles in the
atmosphere is a potential threat to the health of humans, live-
stock, wildlife, and ecosystems, military agencies in the US
have conducted risk assessments [1]; in particular, the safety
profile of TNAZ [2], structurally similar to RRx-001 had al-
ready been comprehensively characterized, suggesting that
the development of dinitroazetidine containing compounds
were inherently less risky. The availability of toxicology in-
formation was a significant advantage since GLP-repeated
dose toxicology studies cost millions of US dollars [3] and
take up to or over a year to complete.
In addition, since the chemistry of energetic com-
pounds is based on free radical-initiated chain reactions,
synergy with radiation therapy was suggested, given that
the outcome of the latter depends on the generation of
reactive oxygen species [4]. Free radical production was also
expected because 1,3,3 trinitroazetidine (TNAZ) [5], an ex-
plosive propellant for guns, artillery, mortars and rockets, and
the closest chemical analog of RRx-001, yielded free radicals
during bond cleavage [6].
* Bryan Oronsky
boronsky@epicentrx.com
1 EpicentRx Inc, 800 W El Camino Real, Suite 180,
Mountain View, CA 94040, USA
2 Stanford University, 875 Blake Wilbur Dr Clinic D,
Stanford, CA 94305, USA
3 InterWest Partners, 2710 Sand Hill Rd #200, Menlo Park,
CA 94025, USA
4 Department of Bioengineering, University of California San Diego
(UCSD), 9500 Gilman Dr, La Jolla, CA 92093, USA
Invest New Drugs (2016) 34:371–377
DOI 10.1007/s10637-016-0326-y
The only examples of pharmaceutical agents with compa-
rable origins to RRx-001 are the antituberculant, iproniazid,
and the antidepressant imipramine [7], derived from leftover
World War II rocket fuel hydralazine as well as the explosive
nitroglycerin (NTG), introduced as a treatment for angina
pectoris [8] several years before Alfred Nobel, the inventor
of dynamite, developed the condition [9]. TNAZ modified
with the removal of a single nitro group (NO2) and substitu-
tion of a bromoacetate group produced a non-explosive deriv-
ative called ABDNAZ, an acronym for 1-bromoacetyl-3,3-
dinitroazetidine, a name later shortened to RRx-001 for
easier-to-use pronunciation and communication. In vivo
RRx-001 demonstrated single-agent activity as well as hyp-
oxic cell radiosensitization [10].
Effects of hypoxia on radiosensitivity
When solid tumor growth exceeds a critical diameter of 1–
2 mm3 (106 cells) [11], diffusion limitations of oxygen and
nutrients from blood vessels located in the periphery leads to
necrotic centers. The resultant activation of the hypoxia induc-
ible factor (HIF) system mediates the expression of VEGF,
erythropoietin and factors regulating glucose transport and
glycolysis such as GLUT-1 and GLUT-3, [12]; the induction
of these genes drives vascular remodeling and a metabolic
switch to aerobic glycolysis, which are integral to malignant
transformation and progression. [13, 14] Due to a dearth of
superoxide, hydrogen peroxide and hydroxyl radicals that ox-
idatively damage macromolecules including lipid, protein and
nucleic acid under low oxygen conditions, the presence of
hypoxia predicts for a poor response to radiotherapy.[15] For
example, nearly 40 % of breast cancers have hypoxic regions
with oxygen concentrations below the threshold required for
half-maximal radiosensitivity (pO2 < 2.5 mmHg), which ad-
versely impacts the response to radiotherapy [16].
As a common feature of most solid tumors, hypoxia, there-
fore, plays a critical role not only in the development of
radioresistance but also chemoresistance. Unlike tumors, and
with the exception of tissues like the retina and the dermis,
normal cells are normally well-oxygenated (>10 mm/Hg O2)
[17]. A clear therapeutic disadvantage, hypoxia is also poten-
tially an exploitable physiological difference, opening the
door to the development of hypoxia-selective agents that are
preferentially toxic only to oxygen-deficient tumor cells. In
particular, the development of the nitroimidazoles as hypoxic
cell sensitizers that mimic the effect of oxygen on tumors
resulted from the discovery that 14C-labelled misonidazole
bound selectively to macromolecules in hypoxic cells both
in vitro and in vivo [18] and were reduced by nitroreductase
enzymes to a radical anion—this reduction only occurs under
hypoxic conditions [19].
Radiosensitizers defined
The term Bradiosensitizer^ refers to an agent that enhances the
therapeutic ratio of radiotherapy for similar levels of normal
Fig. 2 A comparison of the single dose antitumor activity of RRx-001
(ABDNAZ) to cisplatin in murine SCCVII tumor model
Fig. 1 The in vitro activity of
RRx-001 (ABDNAZ) under
normoxia or hypoxia in SCC VII
tumor
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tissue toxicity, which is tantamount to the Holy Grail in radi-
ation oncology and cancer therapy in general because selec-
tive cytotoxicity predicts improved patient tolerance and over-
all quality of life. Like the reaction of oxygen, which leads to
the formation of DNA hydroxyl and peroxyl radicals that di-
rectly attack DNA, radiosensitizers increase the pool of oxi-
dizing species, resulting in enhanced Bfixation^ of free-radical
DNA damage [20].
Unfortunately, however, the history of radiosensitization is
associated with the limited clinical efficacy and substantial nor-
mal tissue toxicity observed with potential radiosensitizers in-
cluding the halogenated pyrimidines [21] and other antimetab-
olites, cisplatin and 5-fluorouracil (5-FU), the nitroimidazoles,
and the hypoxic cytotoxins such as tirapazamine and the
mitomycin-related quinones EO9 and porfiromycin [22, 23].
The lessons learned from the failure of these compounds is
that a radiosensitizer should ideally possess or exhibit:
1) Systemic single agent activity
2) Tumor specificity
3) Sequence-dependent synergy with radiation with no over-
lapping toxicity
4) Activation under hypoxia
5) Broad therapeutic index
6) Normal tissue radioprotection and tumor radiosensitization
Given its novel redox-basedmechanism of radiosensitization,
favorable toxicity profile, and inherent cytotoxicity, RRx-001
fits the definition of a promising carcinoma radiosensitizer,
based on the criteria listed above.
RRx-001 radiosensitization properties
Inherently selective cytotoxicity
RRx-001 is an optimized derivative of TNAZ, a compound
chosen from a collection of energetic polynitro propellant ma-
terials on the basis of a greater increase in IC50 hypoxia com-
pared to normoxia (Fig. 1) [10].
Fig. 4 RRx-001 (ABDNAZ) in murine SCCVII tumor model: potentiation of the effect of radiation. RRx-001 (ABDNAZ) was given at a dose of 5 mg/
kg QD for 5 days. Radiotherapy: 250 cGy QD for 5 days
Fig. 3 RRx-001 (ABDNAZ) in human colon cancer HT29 and murine carcinoma SCC VII cell lines: radiosensitization effects
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In vivo activity of RRx-001 in the SCCVII syngeneic
mouse tumor model demonstrated equivalent activity to
Cisplatin, with no apparent induced side effects, as shown
below (Fig. 2), indicative of promising antitumor activity
and a favorably low acute toxicity profile [10].
Synergistic effects with radiation
In vitro experiments showed that RRx-001 synergistically
enhances XRT-induced inhibition of proliferation of both
radiosensitive SCCVII cells and relatively radioresistant
HT-29 tumor cells (Fig. 3), potentiates the survival of
SCCVII tumor-bearing mice, and significantly improves
the therapeutic ratio of radiotherapy (Fig. 4). Analysis with
Jin’s formula (Q = Ea + b/(Ea + Eb − Ea × Eb) [24] of both in
vitro and in vivo experiments for antagonism, additive effects,
and synergism revealed a synergistic interaction between
RRx-001 and radiation.
Potentiation of radiation-induced growth delay in murine
tumors was both dose and schedule dependent. Maximum
tumor growth delay occurred when RRx-001 was adminis-
tered minutes prior to or concomitant with (during) radiation
(Fig. 5).
The mechanistic basis of radiosensitization is mediated
by an intricate interaction of RRx-001-modified RBCs (on
administration RRx-001 penetrates the red blood cell
membrane and binds irreversibly to a particular residue
hemoglobin, beta Cysteine 93) with the tumor vasculature.
[25, 26] The preferential adhesion of RRx-001 RBCs to the
vascular endothelium is followed by tumor internalization and
catabolization in a Trojan Horse manner, releasing redox active
RRx-001 and RBC metabolites (i.e. nitric oxide [26, 27] iron
and heme) EpicentRx unpublished data.
The beneficial pleiotropic effects of this oxidative damage
include: nitric oxide generation, [28] increased tumor per-
fusion, cell cycle arrest, apoptosis and inhibition of cell
division, inhibition of epigenetic enzymes responsible for
DNA methylation and various histone modifications [29] and
effects on DNA damage and repair pathways. This underlying
mechanism of action is suggested by an expanding body of
preclinical evidence: 1) in a dose dependent manner, RRx-001
enhanced radiation-induced pro-oxidant production (Fig. 6). 2)
RRx-001 significantly improved tumor blood flow/perfusion
from baseline values compared to control in a murine SCCVII
tumor model. The enhanced blood flow and, by extension,
oxygenation may be, at least, in part, related to the over-
production of nitric oxide (NO) via RRx-001-modified
deoxyhemoglobin under hypoxic conditions that are specific
Fig. 6 a Generation of ROS over
time in HT29 tumor cells by RRx-
001 (ABDNAZ) with and without
radiation. b Generation of ROS in
SCVII tumor cells by RRx-001
(ABDNAZ) with and without
radiation
Fig. 5 Tumor growth delay (TGD) and time between RRx-001
(ABDNAZ) dosage and radiation in murine SCCVII tumor model.
p = 0.05 RRx-001 (ABDNAZ) t = 0 and t = 24 h; p = 0.09 RRx-001
(ABDNAZ) t = 0 and t = 2 h
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to cancer cells (Fig. 7). Exposure of HT-29 cells RRx-001
results in the formation of a dose-dependent increase in
DNA double strand breaks assessed by the measurement of
gamma-H2AX, a biomarker of DNA damage (Fig. 8) [10].
Conclusion and future directions
Despite the demonstration of activity as a chemosensitizer,
chemo-resensitizer [29, 30] and immunosensitizer in multiple
tumor types, RRx-001 has continued along the development
path of radiosensitization: currently two Phase I/II clinical
trials are underway in brain metastases with whole brain ra-
diotherapy (WBRT) and in primary GBM with radiation and
temozolomide. The emerging data is highly positive, albeit
limited and preliminary. These caveats notwithstanding, the
activity profile of RRx-001 + radiation therapy suggests syn-
ergistic cancer cell cytotoxicity in the absence of any neuro-
logical toxicity, which would likely support multicenter Phase
III clinical trials with concurrent radiation and chemoradiation
in these indications.
The percentage of cancer patients that will receive radiation
therapy (RT) at some time during their course of their disease
is approximately 50–60 %.[31] A well-characterized dose-
response relationship between malignant and normal tissue
has been described: higher exposures of radiation lead to
better responses; at sufficiently high doses RT sterilizes
even Bradioresistant^ tumors. Likewise for normal tissues,
where higher doses lead to greater damage, [32], treatment
related toxicity is a major cause for the failure of radio-
therapy. A potential solution to this insuperable problem is
radiosensitization; therefore, despite the laundry list of
previously failed radiosensitizers such as misonidazole,
motexafin gadolinium (Xcytrin), Efaproxyn (efaproxiral or
RSR-13) and bortozemib (Velcade), tirapazamine, RSR-13,
eniposide, topotecan, paclitaxel, cisplatin and IUDR,
tumor-targeted radiosensitization remains an attractive, if
utopian, strategy to improve local control or cure rates.
However, the feasibility of radiosensitization as a therapeu-
tic strategy ultimately depends on the optimization of the del-
icate balance between efficacy and normal tissue toxicity. The
use of the quinone Mitomycin C, for example, despite a pref-
erential toxicity for hypoxic tumor cells, is limited due to
cumulative myelosuppression. [33] Likewise, tirapazamine,
the first hypoxic cytotoxin to enter clinical trials [34], may
prematurely ‘preactivate’ in tissues with a modest degree of
hypoxia such as the retina and dermis (1.5 % oxygen) before
reaching the true hypoxic core of the tumor (0.5 % oxygen),
leading to relatively poor selectivity for neoplastic cells and a
narrow therapeutic index.
Given its solid-tumor efficacy profile, minimal toxicity,
hypoxic cell preference, unique mechanism of action and
Fig. 8 RRx-001 (ABDNAZ) induced DNA damage measured by degree
of induction of γH2AX positive cells
Fig. 7 RRx-001 (ABDNAZ) causes and increase in blood perfusion and blood volume in murine SCCVII tumor model. The slope represents relative
rate of tumor blood perfusion and the level of the plateau represents relative blood volume
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synergy with radiation, RRx-001 has the potential to fill this
treatment vacuum in the therapeutic arsenal as a radiosensitizer.
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